Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

Katarina Luptakova, MD, Michelle Kim, Pamela Ely, MD, PhD, Barbara Grant, MD, John Anthony Parker, MD, PhD, Dimitrios Tzachanis, MD, PhD, Jacalyn Rosenblatt, MD, MSc, James Levine, MD, David Avigan, MD, Robin Joyce, MD

Blood (2010) 116 (21): 2866.

https://doi.org/10.1182/blood.V116.21.2866.2866

Published: 2010

Journal Articles

90 Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Michael S. Buff, MD, Anna Royer, BA, Pamela Ely, MD, PhD, Barbara Grant, MD, J. Anthony Parker, MD, PhD, Robin M. Joyce, MD

Blood (2006) 108 (11): 2752.

https://doi.org/10.1182/blood.V108.11.2752.2752

Published: 2006

Journal Articles

Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma (NHL).

Pamela Ely, MD, PhD, Diane M. Stearns, ARNP, Bassem I. Zaki, MD, Thomas F. Fitzmaurice, Ph.D, Marc Gautier, MD, Christopher H. Lowrey, MD, Elizabeth M. Bengtson, MD, John M. Hill, MD, Anna D. Schaal, ARNP, Elizabeth A. Kimtis, ARNP, Lynn Root, RN, Susan Webber, MT (ASCP), BB, Zbigniew M. Szczepiorkowski, MD, Ph.D, Kenneth R. Meehan, MD

Blood (2005) 106 (11): 5517.

https://doi.org/10.1182/blood.V106.11.5517.5517

Published: 2005

Journal Articles

Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.

Jeffrey A. Bubis, DO, Pamela Ely, MD, PhD, Kenneth R. Meehan, MD, Diane Stearns, ARNP, Anna D. Schaal, ARNP, Elizabeth A. Kimtis, ARNP, Christopher Lowrey, MD, Elizabeth M. Bengtson, MD, John Hill, MD, Marc Gautier, MD

Blood (2005) 106 (11): 4633.

https://doi.org/10.1182/blood.V106.11.4633.4633

Published: 2005

Journal Articles

Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune Recovery.

Elizabeth Bengtson, MD, Jia-Yan Wu, PhD, Thomas Fitzmaurice, PhD, Cornelius J. Cornell, MD, Pamela Ely, MD, Marc Gautier, MD, John Hill, MD, Christopher H. Lowrey, MD, Kenneth Meehan, MD

Blood (2004) 104 (11): 5228.

https://doi.org/10.1182/blood.V104.11.5228.5228

Published: 2004

NARROW

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

90 Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma (NHL).

Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.

Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune Recovery.

Email alerts

ASH Publications

American Society of Hematology

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

90 Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma (NHL).

Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes.

Immunotherapy Immediately Following Transplantation for Multiple Myeloma: Early Recovery of Aggressive Cytotoxic Cells and Improved Immune Recovery.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only